// App-Quantinova.ai

1470 : Impact of Anti-Drug Antibody and Injection Site Reaction on Efficacy: 24-Week Results from a Phase III Study Comparing SB4 (etanercept biosimilar) with Reference Etanercept in Patients with Rheumatoid Arthritis

Researchers

Presenter

  • Jiri Vencovsky

Principal Investigators

  • Paul Emery

  • Edward C. Keystone

  • Jeehoon Ghil

  • Soo Yeon Cheong

  • Evelyn Hong

Medical Centers

  • Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Czech Republic

  • NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leed & Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • University of Toronto, Toronto, ON, Canada

  • Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)

Locations

  • Czech Republic

  • United Kingdom

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • TNF Receptor Superfamily Member 1B

Drug/Treatment

  • Etanercept biosimilar

  • Methotrexate

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved